Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Lyell Immunopharma (LYEL) has 3 years of Non-Current Deffered Revenue data on file, last reported at $37.2 million in Q3 2022.

• For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 54.61% year-over-year to $37.2 million; the trailing twelve-month figure through Sep 2022 stood at $37.2 million (down 54.61% YoY), and the FY2021 full-year result was $79.7 million, down 10.56% from the prior year.
• Non-Current Deffered Revenue grew to $37.2 million in Q3 2022, from $32.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $89.1 million in Q4 2020 to a low of $32.9 million in Q2 2022.
• A 3-year average of $68.6 million and a median of $79.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue dropped 10.56% in 2021 and tumbled 59.79% in 2022, its largest moves.
• Tracing LYEL's Non-Current Deffered Revenue over 3 years: stood at $89.1 million in 2020, then decreased by 10.56% to $79.7 million in 2021, then sank by 53.35% to $37.2 million in 2022.
• Business Quant data shows LYEL's Non-Current Deffered Revenue at $37.2 million in Q3 2022, $32.9 million in Q2 2022, and $77.9 million in Q1 2022.